General

Optogenerapy > General

The European Optogenerapy project has developed the first subcutaneous biophotonic implant using optogenetic technology to deliver doses of therapeutic proteins to patients with Multiple Sclerosis. The device has been pre-clinically validated and features a printed circuit board that activates a light source which controls therapeutic Interferon Beta (IFN-ß) protein production by genetically engineered cells confined within the implant. Biotza Gutiérrez, the consortium’s coordinator from Eurecat...

Read More

Researchers from the Erasmus School of Health Policy & Management of the Erasmus University Rotterdam have done a systematic literature review using scientific databases to retrieve publications on the needs and preferences of relapsing-remitting multiple sclerosis patients when making treatment decisions. The publications analysed shed light on the patients’ needs and preferences regarding treatment decisions.   The literature review suggests that for multiple sclerosis patients the most important treatment characteristics...

Read More
NEOS design thinking session optogenerapy

By Mireia Dilmé - Exploitation, Innovation and Strategy Consultant at Eurecat   Optogenerapy partner NEOS Surgery benefitted from the innovation management task of the project with the organization of a Design Thinking session to brainstorm around the design of a new surgical instrument for Optogenerapy’s device subcutaneous implantation. The design thinking and SCAMPER methodology were applied during the session, which resulted in two concepts selected. Prototypes are...

Read More

By Mireia Dilmé - Exploitation, Innovation and Strategy Consultant at Eurecat   In today's ever-changing market environment, managing innovation effectively has become a key determinant of competitiveness and growth, allowing organisations to cross new performance thresholds. Three conditions are the baseline of innovation: it challenges orthodoxy, it is systemic and it advances over time.   Whilst most enterprises are aware of the importance of establishing formal procedures and methods...

Read More

Barcelona, 1st June, 2017 – Researchers from eleven institutions and companies in seven different European countries have started work within the Optogenerapy consortium to develop optogenetic cellular therapy implants by means of printed electronics with biocompatible materials that will enable the administration of therapeutic protein doses for patients with multiple sclerosis, an illness that affects 2.3 million people all over the world and 700,000 in...

Read More
Do NOT follow this link or you will be banned from the site!